Comparison · NCT00325442-sae
Active vs Placebo Arm: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Active vs Placebo Arm: serious adverse events. Trial comparisons, record NCT00325442-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00325442-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.184 | 0.133 | 0.248 | wilson | |
| Risk in group 2 | 0.188 | 0.137 | 0.252 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00359 | -0.0852 | 0.0782 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.981 | 0.632 | 1.52 | log | |
| Odds ratio, group 1 over group 2 | 0.977 | 0.57 | 1.67 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Active than on Placebo Arm | 278 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Active | Subjects in this arm were randomly allocated to receive oral treprostinil twice daily. | 32 | 174 | EG001 |
| Group 2 | Placebo Arm | Subjects were randomly allocated to receive oral placebo twice daily. | 33 | 176 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were recorded throughout the 16 week study which was conducted between October 2006 and September 2008.
Source ClinicalTrials.gov
Trial
- Title
- FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
- NCT number
- NCT00325442
- Phases
- PHASE3
- Conditions
- Pulmonary Hypertension
- Interventions
- Oral treprostinil (UT-15C) sustained release tablets, Placebo
- Lead sponsor
- United Therapeutics
- Results first posted
- 2013-06-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00325442?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00325442-sae